Viliciguat drug complex and its application in the prevention of heart failure after acute myocardial infarction

By physically adsorbing MES and MOPS amphoteric buffer groups on the surface of porous microspheres to regulate pH, the co-mixing of veliciguanide and modified cardioprotective agents was promoted, solving the problem of low solubility of veliciguanide in the intestine and achieving the effect of multi-target synergistic prevention of heart failure after acute myocardial infarction.

CN123059074APending Publication Date: 2026-11-10JILIN UNIV FIRST HOSPITAL
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202611587731.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-10-14
Publication Date
2026-11-10

AI Technical Summary

Technical Problem

In existing technologies, veliciguat has low solubility in the neutral to weakly alkaline environment of the intestine, resulting in incomplete absorption and low bioavailability. Furthermore, it cannot effectively prevent heart failure after acute myocardial infarction, and existing solutions cannot achieve multi-target synergistic intervention.

Method used

By precisely controlling the pH of the reaction system through the physical adsorption of MES and MOPS amphoteric buffer groups on the surface of porous microspheres, the co-compounding of veliciguanide and modified cardioprotective agents is promoted. Morinda officinalis polysaccharide is used to activate the AMPK signaling pathway to improve cardiomyocyte energy metabolism, and the anti-inflammatory effect is achieved by inhibiting the NF-κB, MAPKs and Akt signaling pathways through 3,5-dihydroxybibenzyl acetate derivative, thus achieving multi-target synergistic prevention.

Benefits of technology

It significantly improves the dissolution and absorption of veliciguat in the intestine, enhances bioavailability, and effectively prevents heart failure after acute myocardial infarction through multi-target synergistic effects, improves LVEF and LVFS in heart failure models, and reduces myocardial collagen volume fraction and TNF-α levels.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123059074A_ABST
    Figure CN123059074A_ABST
Patent Text Reader

Abstract

This invention proposes a veliciguat drug complex and its application in preventing heart failure after acute myocardial infarction, belonging to the field of pharmaceutical preparation technology. The complex comprises veliciguat and a modified cardioprotective agent composed of a 3,5-dihydroxybibenzyl acetate derivative and Morinda officinalis polysaccharide, loaded onto liposomes, PLGA, or chitosan nanoparticles. Its preparation utilizes cross-linked polystyrene porous microspheres with surface physical adsorption of MES and MOPS amphoteric buffer groups, precisely controlling the pH of the reaction system between 5.5 and 7.8, thus solving the problem of low pH-dependent solubility of veliciguat. Veliciguat activates the sGC-cGMP pathway to combat fibrosis, Morinda officinalis polysaccharide activates AMPK and upregulates SIRT1 to inhibit the NLRP3 inflammasome, and the 3,5-dihydroxybibenzyl acetate derivative inhibits the NF-κB / MAPKs / Akt pathway, achieving synergistic effects across multiple targets.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of pharmaceutical preparation technology, and specifically relates to the veliciguat drug complex and its application in the prevention of heart failure after acute myocardial infarction. Background Technology

[0002] Acute myocardial infarction (AMI) is one of the leading causes of death from cardiovascular disease. While the availability of reperfusion therapy has significantly reduced the acute mortality rate of AMI patients, ventricular remodeling after infarction remains a key pathological process leading to heart failure, severely impacting long-term prognosis. Therefore, effective early intervention after myocardial infarction to prevent heart failure is a crucial clinical problem that urgently needs to be addressed in the cardiovascular field.

[0003] Vericiguat is a novel oral soluble guanylate cyclase (sGC) stimulant, currently approved for the treatment of chronic heart failure with reduced ejection fraction (HFrEF). However, vericiguat belongs to Biopharmaceutical Class II, and its solubility is significantly pH-dependent. Its solubility is only 0.9 mg / L in phosphate buffer (pH 6.8), 2 mg / L in acetate buffer (pH 4.5), and only reaches 247 mg / L in hydrochloric acid solution (pH 2). The pH environment varies significantly in different parts of the human gastrointestinal tract (stomach pH 1–3, small intestine pH 5–8). Vericiguat's extremely low solubility in the neutral to weakly alkaline intestinal environment leads to incomplete absorption and low bioavailability in its primary absorption site (small intestine). Furthermore, vericiguat exhibits a significant food effect; co-administration with food can significantly affect its pharmacokinetic behavior.

[0004] To address the aforementioned issues, the existing technology CN121370795A proposes a velixika sustained-release tablet and its preparation method. The regulator used in this method is a free small molecule organic acid, which is only applicable to solid dosage form granulation processes and does not have dynamic buffering capacity, thus failing to maintain the pH of the system stably during liquid-phase compounding. Existing technology CN119185590B proposes the application of hydroxypropyl-β-cyclodextrin in the preparation of veliciguat solid dosage forms, the solid dosage forms, and the preparation method. This method achieves drug solubilization and improves veliciguat's dissolution stability by forming an inclusion complex with hydroxypropyl-β-cyclodextrin. However, this approach only addresses the solubilization of a single drug and is a solid dosage form inclusion technology. It cannot be used for combining veliciguat with multiple cardioprotective active ingredients in a liquid system, and therefore cannot achieve multi-target synergistic intervention in the pathological aspects of heart failure following acute myocardial infarction. On the other hand, Morinda officinalis polysaccharide has antioxidant, anti-inflammatory, and stress-induced myocardial damage-reducing effects; 3,5-dihydroxybenzyl acetate derivatives belong to the bibenzyl group and are known to have anti-inflammatory and antioxidant biological activities. However, existing technologies do not report on the combined use of veliciguat with the above two for the prevention of heart failure following acute myocardial infarction, nor do they present any technical solutions for achieving efficient compounding of the three through pH control.

[0005] Therefore, there is an urgent need for a drug complex that can precisely control the pH of the composite system during the preparation stage, enabling efficient compounding of veliciguat and modified cardioprotective agents, removing the pH-regulating medium after compounding, and loading the resulting drug complex onto nanomaterials, thereby improving the dissolution and absorption of veliciguat in the neutral to weakly alkaline environment of the intestine, increasing oral bioavailability, and synergistically preventing heart failure after acute myocardial infarction through multiple targets. Summary of the Invention

[0006] To address the technical problems existing in the prior art, this invention provides the application of veliciguat in the preparation of drugs for preventing heart failure after acute myocardial infarction. By physically adsorbing MES and MOPS amphoteric buffer groups on the surface of porous microspheres to precisely control the pH value of the reaction system, the invention promotes the blending and compounding of veliciguat with modified cardioprotective agents. Through Morinda officinalis polysaccharide activation of the AMPK signaling pathway to improve cardiomyocyte energy metabolism, upregulation of SIRT1 to inhibit NLRP3 inflammasome-mediated inflammatory response, and the inhibition of NF-κB, MAPKs and Akt signaling pathways by 3,5-dihydroxybibenzyl acetate derivatives to exert anti-inflammatory effects, the invention achieves the technical effect of multi-target synergistic prevention of heart failure after acute myocardial infarction.

[0007] This invention provides a veliciguat drug complex, comprising veliciguat and a modified cardioprotective agent; wherein, The modified cardioprotective active agent comprises a 3,5-dihydroxybibenzyl acetate derivative and Morinda officinalis polysaccharide. The 3,5-dihydroxybibenzyl acetate derivative is 3,5-dihydroxybibenzyl diacetate. The content of polysaccharide in the Morinda officinalis polysaccharide is... 90%; The drug complex is loaded onto a nanomaterial, which is any one of liposomes, PLGA nanoparticles, or chitosan nanoparticles.

[0008] Further, the drug complex is prepared by the following steps: adding porous microspheres to deionized water, wherein the porous microspheres account for 1.0~2.5 wt% of the aqueous phase system; under the pH control of the porous microspheres, first stirring and compounding 3,5-dihydroxybibenzyl acetate derivative and Morinda officinalis polysaccharide in the aqueous phase system to obtain a modified cardioprotective activator; then adding veliciguanide and stirring and compounding; centrifuging or filtering to obtain the drug complex; and then adding nanomaterials to load the drug complex onto the nanomaterials.

[0009] Furthermore, the porous microspheres are cross-linked polystyrene porous microspheres.

[0010] Furthermore, the cross-linked polystyrene porous microspheres have a particle size of 6~30μm.

[0011] Furthermore, the cross-linked polystyrene porous microspheres exhibit surface physical adsorption of MES and MOPS amphoteric buffer groups.

[0012] Furthermore, the pH adjustment range is 5.5 to 7.8.

[0013] Furthermore, the mass ratio of the velixiva to the modified cardioprotective agent is (5~10):(1~2).

[0014] Furthermore, the mass ratio of the 3,5-dihydroxybibenzyl acetate derivative to the Morinda officinalis polysaccharide is 1:1.

[0015] Another aspect of the present invention provides the use of the veliciguat drug complex in the preparation of a drug for preventing heart failure after acute myocardial infarction, wherein the drug complex is the aforementioned drug complex.

[0016] The cross-linked polystyrene porous microspheres used in this invention have a particle size of 6-30 μm. They not only possess the general characteristics of polymer microspheres, such as good sphericity, large specific surface area, and controllable particle size, but also exhibit high rigidity, resistance to dissolution by common solvents, and poor biodegradability. Two zwitterionic buffer derivatives, MES (2-morpholinoethanesulfonic acid) and MOPS (3-morpholinopropanesulfonic acid), are physically adsorbed onto the surface of these porous microspheres. MES has a pKa of 6.10 at 25°C, with an effective buffering range of pH 5.5-6.7; MOPS has a pKa of 7.20 at 25°C, with an effective buffering range of pH 6.5-7.9. The combined use of these two compounds extends the buffering range to pH 5.5-7.9, covering the range from weakly acidic to near-neutral.

[0017] Vericigulet, as a soluble guanylate cyclase (sGC) stimulator, exerts its anti-myocardial fibrosis and vascular endothelial function through a dual mechanism of directly stimulating sGCs without relying on endogenous NO and synergistically enhancing sGC sensitivity to NO. Morinda officinalis polysaccharide improves energy metabolism in ischemia-reperfusion-damaged cardiomyocytes by activating the AMPK signaling pathway and mediates oxidative stress by regulating the AMPK / Nrf2 / HO-1 signaling pathway. Simultaneously, it reduces oxidative stress damage in ischemic myocardium by upregulating SIRT1 and inhibiting NLRP3 inflammasome-mediated inflammatory responses. 3,5-Dihydroxybibenzylacetate derivatives exert anti-inflammatory effects by inhibiting the activation of NF-κB, MAPKs, and Akt signaling pathways and reducing the release of the pro-inflammatory cytokine TNF-α.

[0018] Specifically, the amino group (-NH-) in the veliciguane molecule can form hydrogen bonds with the carbonyl oxygen (C=O, hydrogen bond acceptor) on the acetyl group of 3,5-dihydroxybibenzyl diacetate and with the hydroxyl group (-OH, hydrogen bond donor) on the Morinda officinalis polysaccharide molecule chain. Furthermore, π-π stacking interactions can occur between the aromatic rings in the molecular structures of these three compounds, further stabilizing the complex structure and synergistically preventing heart failure after acute myocardial infarction by activating the sGC-cGMP pathway, improving myocardial energy metabolism, and inhibiting inflammatory responses.

[0019] The beneficial effects of the embodiments of the present invention are as follows: (1) By combining veliciguat with modified cardioprotective agents (Morinda officinalis polysaccharide and 3,5-dihydroxybenzyl acetate derivative), a multi-pathway synergistic network is formed: veliciguat activates the sGC-cGMP pathway to fight fibrosis, Morinda officinalis polysaccharide activates AMPK to improve energy metabolism and upregulates SIRT1 to inhibit NLRP3 inflammasome, and the derivative inhibits the NF-κB / MAPKs / Akt pathway to fight inflammation. This synergistically prevents heart failure from multiple levels, including anti-fibrosis, energy metabolism, and inflammation suppression.

[0020] (2) Animal experiments showed that the nano-formulation loaded with this complex (Examples 4-6) could significantly improve LVEF (63.5%-68.2%) and LVFS in a heart failure model, and effectively reduce myocardial collagen volume fraction and TNF-α inflammatory factor levels. Its efficacy was significantly better than that of veliciguat alone (Comparative Example 2) and riociguat complex (Comparative Example 1), verifying the high synergistic specificity among the components of the complex. Attached Figure Description

[0021] Figure 1 This is a flowchart of the preparation method of the drug complex in Example 1 of the present invention. Detailed Implementation

[0022] The technical solution of the present invention will be clearly and completely described below with reference to the embodiments. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those of ordinary skill in the art without creative effort are within the scope of protection of the present invention.

[0023] The Morinda officinalis polysaccharide used in the embodiments of this disclosure was purchased from Victor Biotechnology, product number: WKQ-0008910 (specification: 100mg per vial, content...). 90%); the remaining reagents and equipment not specified were all standard and commercially available.

[0024] Preparation Example 1 Preparation of porous microspheres Preparation methods include: S1. Microsphere Pretreatment: Take 10g of cross-linked polystyrene porous microspheres (Suzhou Nanomicro Life Science & Technology, particle size 6~30μm), place them in a 250mL three-necked flask, add 100mL of methanol, and mechanically stir and wash at room temperature for 30min at 250rpm. Filter and collect the microspheres. After washing, filter using a sintered glass funnel with a negative pressure of 0.02~0.04MPa and collect the microsphere filter cake. Add 100mL of deionized water to the microspheres, and wash at room temperature (25℃) with stirring at 300rpm for 30min. Filter and collect the microsphere filter cake under the same conditions. Repeat the methanol washing-water washing-filtration process twice to remove residual porogens, uncross-linked monomers, and small molecule oligomer impurities from microsphere preparation. Transfer the washed microsphere filter cake to a vacuum drying oven. -0.09MPa, drying temperature 50℃, constant temperature vacuum drying for 12h; after drying, take it out and place it in a desiccator to cool to room temperature, then seal and store for later use.

[0025] S2. Preparation of adsorption solution: Weigh out MES (2-morpholinoethanesulfonic acid, purity...) 2.80g of 99.0% pure MOPS (3-morpholinopropanesulfonic acid, purity) 2.30 g of 99.0% MES was placed in a 250 mL beaker; 100 mL of methanol-water solution (methanol to water volume ratio 1:1) was added; the methanol was chromatographically pure and the water was ultrapure water; a watch glass was placed on the beaker, and the mixture was stirred at 350 rpm for 30 min at room temperature (25 °C) until the solid was completely dissolved, resulting in a homogeneous and transparent MES / MOPS mixed adsorption solution.

[0026] S3, Physical Adsorption: All microspheres pretreated, dried, and cooled in S1 were added to 100 mL of the adsorption solution prepared in S2; transferred to a 250 mL three-necked reaction flask, equipped with a mechanical stirrer, and kept at a system temperature of 25 °C under water bath temperature control, with a stirring speed of 300 rpm. The mixture was continuously stirred for 24 h under sealed conditions to carry out adsorption loading; the adsorption process mainly relies on: the hydrophobic effect of the polystyrene skeleton, capillary retention of porous channels, van der Waals forces, and electrostatic effects.

[0027] S4. Drying: Immediately after adsorption, collect the microspheres using a sand core funnel for rapid filtration under a negative pressure of 0.02~0.04MPa. Rinse the microspheres rapidly with a pre-cooled methanol-water solution (methanol to water volume ratio 1:1) at 0~5℃, using 20mL of solvent per rinse, for a total of two rinses. During rinsing, the solvent flows slowly over the filter cake without stirring or soaking, only removing loosely attached free MES and MOPS from the outer surface of the microspheres. After rinsing, transfer the microspheres to a vacuum drying oven; vacuum degree... -0.09MPa, drying temperature 50℃, constant temperature vacuum drying for 24h; after drying, transfer to a desiccator to cool to room temperature, seal and store to obtain modified porous microspheres with physical adsorption loading of MES / MOPS.

[0028] Preparation Example 2 Preparation of 3,5-dihydroxybibenzyl acetate derivatives The preparation method includes: adding 10g of 3,5-dihydroxybibenzyl acetate and 8.5g of acetic anhydride to a 250mL three-necked flask, using 1.2g of pyridine as a catalyst, connecting a spherical condenser, and placing the flask in a 60℃ magnetic stirrer at 250rpm for 4h. After the reaction, the reaction solution is poured into 100mL of ice water to quench unreacted acetic anhydride. Pyridine reacts with the acetic acid produced in the reaction to form a salt that dissolves in the aqueous phase. The polarity of the acetylated product decreases, and its low solubility in water allows it to be fully separated. The crude solid is collected by filtration and 9.5g is washed three times with deionized water to remove water-soluble salt impurities. 70g of ethanol is added to the crude product for recrystallization at 45℃ and a cooling rate of 0.5~1℃ / min, finally yielding 9g of 3,5-dihydroxybibenzyl acetate derivative (3,5-dihydroxybibenzyl diacetate).

[0029] Example 1: Drug complex (Vivixazole: Modified cardioprotective agent = 5:1) Preparation method (e.g.) Figure 1 (as shown) S1: Take 2.5g of the porous microspheres prepared in Preparation Example 1, add them to 100mL of deionized water, stir and disperse evenly to obtain a porous microsphere suspension (the porous microspheres account for 2.5wt% of the mass of the aqueous phase system).

[0030] S2: 0.5 g of the 3,5-dihydroxybibenzyl acetate derivative prepared in Preparation Example 2 and 0.5 g of Morinda officinalis polysaccharide were added to the above porous microsphere suspension and stirred at room temperature and stirring speed of 300 rpm for 2 h to obtain the modified cardioprotective active agent-porous microsphere composite system.

[0031] S3: Add 5.0 g of velixicam to the above system and continue stirring at room temperature and a stirring speed of 300 rpm for 3 h. During the compounding process, the amphoteric buffer groups of MES and MOPS physically adsorbed on the surface of the porous microspheres stabilize the pH of the reaction system in the range of 5.5~7.8 through proton dissociation equilibrium.

[0032] S4: After the composite reaction is complete, centrifuge the reaction solution at 4000 rpm for 10 min, collect the supernatant, and then centrifuge at 10000 rpm for 15 min to collect the precipitate (excluding porous microspheres). Wash the precipitate three times with deionized water, resuspend the precipitate in a protective solution containing 5% w / v mannitol-sucrose (1:1), pre-freeze at -45℃ for 4 h, dry once at -25℃ / 0.15 mbar for 24 h, and then at 30℃ / After secondary drying at 0.02 mbar for 6 hours, the drug complex was obtained.

[0033] Example 2: Preparation of drug complex (Viliciguat: Modified cardioprotective agent = 10:1) Preparation method: S1: Take 1.0 g of the porous microspheres prepared in Preparation Example 1, add it to 100 mL of deionized water, stir and disperse evenly to obtain a porous microsphere suspension (the porous microspheres account for 1.0 wt% of the mass of the aqueous phase system).

[0034] S2: 0.2 g of the 3,5-dihydroxybibenzyl acetate derivative prepared in Preparation Example 2 and 0.2 g of Morinda officinalis polysaccharide were added to the above porous microsphere suspension and stirred for 3 h at room temperature and stirring speed of 200 rpm to obtain the modified cardioprotective active agent-porous microsphere composite system.

[0035] S3: Add 4.0 g of velixicam to the above system and continue stirring at room temperature and a stirring speed of 200 rpm for 4 h. During the compounding process, the amphoteric buffer groups of MES and MOPS physically adsorbed on the surface of the porous microspheres stabilize the pH of the reaction system in the range of 5.5~7.8 through proton dissociation equilibrium.

[0036] S4: After the composite reaction is complete, centrifuge the reaction solution at 4000 rpm for 10 min, collect the supernatant, and then centrifuge at 10000 rpm for 15 min. Collect the precipitate, wash it three times with deionized water, and resuspend the precipitate in a protective solution containing 5% w / v mannitol-sucrose (1:1). Pre-freeze at -45℃ for 4 h, dry once at -25℃ / 0.15 mbar for 24 h, and then at 30℃ / After secondary drying at 0.02 mbar for 6 hours, the drug complex was obtained.

[0037] Example 3: Preparation of the drug complex (Vilicigua: Modified cardioprotective agent = 7.5:1) Preparation method: S1: Take 3.0 g of the porous microspheres prepared in Preparation Example 1, add them to 120 mL of deionized water, stir and disperse evenly to obtain a porous microsphere suspension (the porous microspheres account for 2.5 wt% of the mass of the aqueous phase system).

[0038] S2: 0.5 g of the 3,5-dihydroxybibenzyl acetate derivative prepared in Preparation Example 2 and 0.5 g of Morinda officinalis polysaccharide were added to the above porous microsphere suspension and stirred at room temperature and stirring speed of 350 rpm for 2 h to obtain the modified cardioprotective active agent-porous microsphere composite system.

[0039] S3: Add 7.5g of velixicam to the above system and continue stirring at room temperature and a stirring speed of 350rpm for 3h. During the compounding process, the amphoteric buffer groups of MES and MOPS physically adsorbed on the surface of the porous microspheres stabilize the pH of the reaction system in the range of 5.5~7.8 through proton dissociation equilibrium.

[0040] S4: After the composite reaction is complete, centrifuge the reaction solution at 4000 rpm for 10 min, collect the supernatant, and then centrifuge at 10000 rpm for 15 min. Collect the precipitate, wash it three times with deionized water, and resuspend the precipitate in a protective solution containing 5% w / v mannitol-sucrose (1:1). Pre-freeze at -45℃ for 4 h, dry once at -25℃ / 0.15 mbar for 24 h, and then at 30℃ / After secondary drying at 0.02 mbar for 6 hours, the drug complex was obtained.

[0041] Example 4: Preparation of drug complex loaded onto PLGA nanoparticles Preparation method: S1: Prepare the drug complex lyophilized powder according to the method of Example 1.

[0042] S2: Weigh 200 mg of PLGA (molecular weight 20 kDa) and dissolve it in 10 mL of dichloromethane to form an oil phase.

[0043] S3: Weigh 50 mg of the drug complex prepared in Example 1, disperse it in 5 mL of deionized water, and add 20 mL of 1.0 wt% polyvinyl alcohol (PVA) aqueous solution as the aqueous phase.

[0044] S4: Slowly drip the oil phase into the aqueous phase and shear it for 5 minutes at 12,000 rpm using a high-speed shear disperser under ice-water bath conditions to form a primary emulsion.

[0045] S5: Transfer the colostrum into 100 mL of 0.5 wt% PVA aqueous solution, and evaporate the organic solvent by magnetic stirring (600 rpm) at room temperature for 4 h to completely evaporate the dichloromethane and solidify the PLGA to form drug-loaded nanoparticles.

[0046] S6: Centrifuge the nanoparticle suspension at 10,000 rpm for 20 min, collect the precipitate, wash three times with deionized water, add a lyophilization protectant (mannitol to sucrose mass ratio 1:1, total amount 5% w / v), stir to dissolve evenly, dispense into containers, and place in a freeze dryer; pre-freeze at -45℃ for 4 h, dry once at a vacuum of 0.15 mbar and shelf temperature of -25℃ for 24 h, and then dry again at a vacuum of... PLGA nanoparticles loaded with drug complex were obtained by secondary drying at 0.02 mbar and shelf temperature of 30 °C for 6 h.

[0047] S7: The average particle size of the obtained PLGA nanoparticles was 185±23nm, the polydispersity index (PDI) was 0.12, and the zeta potential was -18.6mV, as determined by a dynamic light scattering particle size analyzer. This indicates that the nanoparticles have a uniform particle size distribution and good stability.

[0048] Example 5: Preparation of drug complex loaded onto liposomes Preparation method: S1: Prepare the drug complex lyophilized powder according to the method of Example 2.

[0049] S2: Weigh 120mg of soybean lecithin and 30mg of cholesterol, dissolve them in 10mL of anhydrous ethanol, and stir in a 40℃ water bath to form a lipid phase.

[0050] S3: Weigh 40 mg of the drug complex prepared in Example 2 and dissolve it in 20 mL of pH 6.5 phosphate buffer as a hydration medium.

[0051] S4: Slowly inject the lipid phase into the hydration medium and hydrate it for 30 minutes in a 40°C water bath with magnetic stirring (500 rpm) to form a liposome suspension.

[0052] S5: Place the liposome suspension in an ice-water bath and use a probe ultrasonic disruptor (200W, 3s operation, 5s interval) to sonicate 10 times to reduce the liposome particle size.

[0053] S6: The sonicated liposome suspension was extruded through 0.45μm and 0.22μm polycarbonate membranes five times each to obtain liposomes loaded with drug complex.

[0054] S7: Centrifuge the liposome suspension at 12000 rpm for 30 min, collect the precipitate, wash twice with deionized water, add lyophilization protectant (mannitol to sucrose mass ratio 1:1, total amount 5% w / v), stir to dissolve evenly, dispense, and place in a freeze dryer; pre-freeze at -45℃ for 4 h, dry once at a vacuum of 0.15 mbar and shelf temperature of -25℃ for 24 h, and then dry again at a vacuum of... The liposome lyophilized powder loaded with the drug complex was obtained by secondary drying at 0.02 mbar and shelf temperature of 30°C for 6 hours.

[0055] S8: Observed by transmission electron microscopy, the obtained liposomes are spherical or near-spherical, with a particle size distribution range of 120~160nm.

[0056] Example 6: Preparation of drug complex loaded onto chitosan nanoparticles Preparation method: S1: Prepare the drug complex lyophilized powder according to the method of Example 1.

[0057] S2: Weigh chitosan (degree of deacetylation) 90% (molecular weight 50kDa) 100mg was dissolved in 50mL of 1.0% acetic acid aqueous solution and magnetically stirred at room temperature until completely dissolved. The solution was filtered through a 0.45μm filter membrane to remove insoluble matter, thus obtaining a chitosan solution.

[0058] S3: Weigh 20 mg of sodium tripolyphosphate (TPP), dissolve it in 10 mL of deionized water, and filter it through a 0.22 μm filter membrane to obtain a TPP crosslinking agent solution.

[0059] S4: Weigh 30 mg of the drug complex prepared in Example 1, disperse it in 10 mL of deionized water, add it to the above chitosan solution, and mix it evenly with magnetic stirring (400 rpm) at room temperature.

[0060] S5: While stirring, slowly drip the TPP solution into the chitosan-drug complex mixture using a syringe at a rate of 0.5 mL / min. After the addition is complete, continue stirring for 30 min. The system will spontaneously form drug-loaded chitosan nanoparticles.

[0061] S6: Centrifuge the nanoparticle suspension at 10,000 rpm for 15 min, collect the precipitate, wash three times with deionized water, add a freeze-drying protectant (trehalose to mannitol mass ratio 2:1, total amount 8% w / v), stir to dissolve evenly, dispense, and place in a freeze dryer; pre-freeze at -45℃ for 4 h, dry once at a vacuum of 0.15 mbar and shelf temperature of -25℃ for 24 h, and then dry again at a vacuum of... Chitosan nanoparticles loaded with drug complex were obtained by secondary drying at 0.02 mbar and shelf temperature of 30 °C for 6 h.

[0062] S7: Scanning electron microscopy revealed that the obtained chitosan nanoparticles were spherical with a particle size distribution of 200~350nm.

[0063] Comparative Example 1 Riocigua drug complex (supported chitosan nanoparticles) Preparation method: S1: Take 2.5g of the porous microspheres prepared in Preparation Example 1, add them to 100mL of deionized water, stir and disperse evenly to obtain a porous microsphere suspension.

[0064] S2: 0.5 g of the 3,5-dihydroxybibenzyl acetate derivative prepared in Preparation Example 2 and 0.5 g of Morinda officinalis polysaccharide were added to the above porous microsphere suspension and stirred for 2 h at room temperature and a stirring speed of 300 rpm.

[0065] S3: Add 5.0g of Riociguat to the above system and continue to stir and compound at room temperature and a stirring speed of 300rpm for 3h.

[0066] S4: After the complex reaction is completed, centrifuge at 4000 rpm for 10 min, take the supernatant, centrifuge at 10000 rpm for 15 min, collect the precipitate, wash three times with deionized water, and freeze dry (same as in Example 1) to obtain the riociguat drug complex.

[0067] S5: Load the complex obtained in S4 onto chitosan nanoparticles to obtain the lioscopia complex loaded with chitosan nanoparticles (the method of loading chitosan nanoparticles is the same as in Example 6).

[0068] Comparative Example 2 Vilixigua solid dosage form Preparation method: S1: Add 20g of cyclodextrin (hydroxypropyl-β-cyclodextrin with an average degree of substitution of 4.5) to 80mL of citric acid aqueous solution with pH 3.0, and stir at 55℃ to dissolve and form hydroxypropyl-β-cyclodextrin solution.

[0069] S2: Add 5g of veliciguanine to approximately 8 times its weight of acetone and stir until homogeneous. Then, slowly add the stirred veliciguanine sample to the hydroxypropyl-β-cyclodextrin solution in S1 in small amounts several times. Continue stirring for 1 hour until complete inclusion. Cool, freeze-dry at -50°C, and pulverize through a 100-mesh sieve to obtain the veliciguanine-cyclodextrin inclusion complex.

[0070] S3: Take the veliciguat-cyclodextrin inclusion complex from S2, add 52g lactose, 35g microcrystalline cellulose, 6g hydroxypropyl methylcellulose, and 4g croscarmellose sodium to a wet granulator, granulate with purified water, pass through a 20-mesh sieve for granulation, dry at 60℃, then pass through a 30-mesh sieve for granulation, add 2g croscarmellose sodium and mix evenly, then add 1.2g magnesium stearate and mix evenly to obtain granules. Compress the granules to obtain veliciguat solid dosage form.

[0071] Comparative Example 3 Drug complexes that do not use porous microspheres to regulate pH Preparation method: S1: 0.5 g of the 3,5-dihydroxybibenzyl acetate derivative prepared in Preparation Example 2 and 0.5 g of Morinda officinalis polysaccharide were directly added to 100 mL of deionized water (without adding any porous microspheres), and stirred for 2 h at room temperature and a stirring speed of 300 rpm.

[0072] S2: Add 5.0 g of veliciguanide to the above system and continue stirring at room temperature and a stirring speed of 300 rpm for 3 hours. No pH adjustment methods are used during the compounding process; the pH changes are solely determined by the system's own pH.

[0073] S3: After the complex reaction is completed, centrifuge at 4000 rpm for 10 min, take the supernatant, centrifuge at 10000 rpm for 15 min, collect the precipitate, wash three times with deionized water, and freeze dry (same as in Example 1) to obtain the complex.

[0074] S4: The preparation method of loading the S3 complex onto chitosan nanoparticles is the same as in Example 6, to obtain a drug complex that does not use porous microspheres to regulate pH.

[0075] Comparative Example 4 Drug complexes with pH-regulated blank porous microspheres Preparation method: S1: Add blank porous microspheres (i.e., cross-linked polystyrene porous microspheres) that have not adsorbed MES / MOPS, and the rest of the operation is exactly the same as in Example 1.

[0076] S2: The preparation method of the chitosan nanoparticles is the same as in Example 6, and a drug complex with pH controlled by blank porous microspheres is obtained.

[0077] Experimental Example 1 In vitro pH stability and buffering capacity verification S1, Samples: Example 6 (chitosan nanoparticles with drug-loaded complex obtained in S6), Comparative Example 3 (drug complex obtained in S4 without pH regulation using porous microspheres), Comparative Example 4 (drug complex with pH regulation using blank porous microspheres obtained in S2).

[0078] S2. Test Method: S201, pH monitoring during preparation process: Following the preparation methods of Example 6, Comparative Example 3, and Comparative Example 4, the pH changes of the reaction system from the initial stage to the end of the compounding process were continuously recorded using an online pH monitor (accuracy ±0.01). The specific recording time points were: initial stage, 5 min after adding 3,5-dihydroxybibenzyl acetate derivative, 5 min and 30 min after adding Morinda officinalis polysaccharide, 5 min, 30 min and 60 min after adding veliciguanide, and the end of the compounding process (3 h).

[0079] Monitoring method of Example 6: The porous microspheres of physical adsorption MES / MOPS prepared in Preparation Example 1 were dispersed in deionized water according to the material ratio of Example 6, and 3,5-dihydroxybibenzyl acetate derivative, Morinda officinalis polysaccharide and veliciguanidine were added in sequence, and the pH value was recorded in real time throughout the process.

[0080] Comparative Example 3 Monitoring Methods: Without adding any porous microspheres, 3,5-dihydroxybibenzyl acetate derivative, Morinda officinalis polysaccharide and veliciguanidine were added directly to deionized water in sequence, compounded under the same stirring conditions, and pH changes were recorded in real time.

[0081] Comparative Example 4 monitoring methods: blank porous microspheres without physical adsorption of MES / MOPS were added to deionized water, and the rest of the operation was the same as in Example 6, with pH changes recorded in real time.

[0082] S3. Experimental Results: The pH monitoring results during the preparation process are shown in Table 1. Table 1 shows that in Example 6, the porous microspheres that physically adsorbed MES and MOPS maintained the pH of the reaction system within the range of 6.32–6.50 throughout the process, with fluctuations not exceeding ±0.18, effectively ensuring that veliciguat maintained a suitable solubility state during the compounding process. In Comparative Examples 3 and 4, the pH fluctuations reached 2.40 and 2.30, respectively, indicating that without the MES / MOPS buffer group, regardless of the presence of porous microsphere carriers, the system could not resist the drastic pH fluctuations caused by the decomposition of each group. When the pH dropped to 4.80, the system became strongly acidic; when the pH rose above 7.0, the solubility of veliciguat decreased sharply to below 0.9 mg / L, and a large amount of drug precipitated in free crystal form, unable to form a stable complex with the modified cardioprotective agent.

[0083] Table 1. pH monitoring results during the preparation process

[0084] Experimental Example 2 Evaluation of the preventive effects of drug-loaded complexes on different nanocarriers on heart failure after acute myocardial infarction. S1. Experimental Methods: An acute myocardial infarction model was established using left anterior descending coronary artery ligation in male SD rats. Surviving rats 24 hours post-surgery were randomly divided into the following groups (n=12 / group): Experimental group: Example 4 group: Gavage administration of the PLGA nanoparticle-loaded drug complex prepared in Example 4 (10 mg / kg / d based on veliciguanine). Example 5 group: Gavage administration of the liposome-loaded drug complex prepared in Example 5 (10 mg / kg / d based on veliciguan). Example 6 group: Chitosan nanoparticle-loaded drug complex prepared in Example 6 was administered by gavage (10 mg / kg / d based on viriciguat). Comparative example group: Comparative Example 1: The riociguat drug complex (loaded with chitosan nanoparticles) prepared by gavage in Comparative Example 1. (Calculated as 10 mg / kg / day based on riociguat); Comparative Example 2: The preparation of veliciguat prepared in Comparative Example 2 was administered by gavage (10 mg / kg / d based on veliciguat). Comparative Example 3: Comparative Example 3 (drug complex obtained from S4 without pH control using porous microspheres) administered by gavage (10 mg / kg / d based on veliciguat); Comparative Example 4: Oral administration of Comparative Example 4 (the drug complex with pH-regulating porous microspheres obtained in S2) (10 mg / kg / d based on veliciguat); Control group: Sham surgery group: Open chest surgery but without ligation of the coronary arteries, and administered an equal volume of normal saline; Model group: After ligation, an equal volume of physiological saline was administered; After 4 weeks of continuous administration, the following indicators were measured: left ventricular ejection fraction (LVEF) and left ventricular fractional shortening (LVFS) by echocardiography; myocardial collagen volume fraction (CVF) by Masson staining to assess the degree of myocardial fibrosis; serum TNF-α level by ELISA; and cardiomyocyte apoptosis index by TUNEL staining.

[0085] S2. Experimental Results: The results of the index detection are shown in Table 2. Table 2 shows that the drug complexes loaded in Examples 4, 5, and 6 were significantly superior to the comparative groups in all detection indicators, including LVEF, LVFS, CVF, TNF-α, and apoptosis index. This indicates that the drug complexes described in this invention can achieve synergistic prevention of heart failure after acute myocardial infarction in different nanocarriers. Among them, Example 4 showed the best effect. After replacing veliciguat with another sGC agonist, riociguat (Comparative Example 1), LVEF decreased from 63.5%~68.2% to 51.6%, indicating that the synergistic effect between veliciguat and the modified cardioprotective activator is component-specific, and not all sGC agonists can achieve the same synergistic effect. The LVEF of Comparative Example 2 was significantly lower than that of the comparative groups. The VEF was 52.8%, significantly inferior to Examples 4-6 of this invention, indicating that this invention achieves a therapeutic effect surpassing that of a single veliciguat formulation through the synergistic combination of veliciguat and the modified cardioprotective active agent. The results from Comparative Examples 3 and 4 show that the pH control method of the porous microspheres adsorbed by MES / MOPS in this invention is a key technical feature for achieving efficient combination of veliciguat and the modified cardioprotective active agent, thereby exerting a synergistic effect. Veliciguat exerts its anti-fibrotic effect by activating the sGC-cGMP pathway; Morinda officinalis polysaccharide improves myocardial energy metabolism by activating the AMPK signaling pathway and inhibits the NLRP3 inflammasome by upregulating SIRT1; and 3,5-dihydroxybibenzyl acetate derivatives exert their anti-inflammatory effect by inhibiting the NF-κB / MAPKs / Akt pathway. These three substances act on different signaling pathways, synergistically exerting their effects on multiple levels, including improving energy metabolism, inhibiting inflammation, anti-fibrosis, and anti-apoptosis. All three nanocarriers can effectively deliver the drug complex to ischemic myocardium, further enhancing the therapeutic effect of the complex.

[0086] Table 2 Indicator Detection Results

[0087] Note: Indicates a comparison with the sham surgery group ; Indicates comparison with the model group .

[0088] In summary, this invention overcomes the inherent bottleneck of veliciguat's solubility dependence by using MES / MOPS physical adsorption porous microsphere pH dynamic control technology. Based on this, a ternary molecular complex system of veliciguat-Morinda officinalis polysaccharide-3,5-dihydroxybibenzyl acetate derivative was established to achieve multi-target and multi-pathway synergistic prevention of heart failure after acute myocardial infarction.

[0089] Although embodiments of the present invention have been shown and described, it will be understood by those skilled in the art that various changes, modifications, substitutions and variations can be made to these embodiments without departing from the principles and spirit of the present invention. All equivalent changes and improvements made within the scope of the present invention should still fall within the patent coverage of the present invention.

Claims

1. A velixivaline drug complex, characterized in that, It contains veliciguanide and a modified cardioprotective agent; among which, The modified cardioprotective active agent comprises a 3,5-dihydroxybibenzyl acetate derivative and Morinda officinalis polysaccharide. The 3,5-dihydroxybibenzyl acetate derivative is 3,5-dihydroxybibenzyl diacetate. The content of polysaccharide in the Morinda officinalis polysaccharide is... 90%; The drug complex is loaded onto a nanomaterial, which is any one of liposomes, PLGA nanoparticles, or chitosan nanoparticles.

2. The pharmaceutical complex according to claim 1, characterized in that, The drug complex is prepared by the following steps: porous microspheres are added to deionized water, with the porous microspheres accounting for 1.0~2.5 wt% of the aqueous phase system. Under the pH control of the porous microspheres, 3,5-dihydroxybibenzyl acetate derivative and Morinda officinalis polysaccharide are first stirred and compounded in the aqueous phase system to obtain a modified cardioprotective activator. Then, veliciguat is added and stirred and compounded. The drug complex is obtained by centrifugation or filtration. Nanomaterials are then added to load the drug complex onto the nanomaterials.

3. The pharmaceutical complex according to claim 2, characterized in that, The porous microspheres are cross-linked polystyrene porous microspheres.

4. The pharmaceutical complex according to claim 3, characterized in that, The cross-linked polystyrene porous microspheres have a particle size of 6~30μm.

5. The pharmaceutical complex according to claim 3, characterized in that, The cross-linked polystyrene porous microspheres are surface-physically adsorbed with MES and MOPS amphoteric buffer groups.

6. The pharmaceutical complex according to claim 2, characterized in that, The pH adjustment range is 5.5 to 7.

8.

7. The pharmaceutical complex according to claim 1, characterized in that, The mass ratio of the velixitoluene to the modified cardioprotective active agent is (5~10):(1~2); the mass ratio of the 3,5-dihydroxybibenzyl acetate derivative to the Morinda officinalis polysaccharide is 1:

1.

8. The application of the veliciguat drug complex in the preparation of drugs for the prevention of heart failure after acute myocardial infarction, characterized in that, The drug complex is the drug complex as described in any one of claims 1 to 7.

Citation Information

Patent Citations

  • Application of hydroxypropyl-β-cyclodextrin in preparing solid preparation of Vericipiracil, solid preparation and preparation method

    CN119185590B

  • Velciguat sustained release tablet and preparation method thereof

    CN121370795A